diabetestalk.net

Hepatogenous Diabetes Treatment

Diabetes And Liver An Association: Hepatogenous Diabetes Mechanism And Some Evidences

Diabetes And Liver An Association: Hepatogenous Diabetes Mechanism And Some Evidences

Ajita Acharya, Eden Wudneh, Radhika Krishnan, Aisha Ashraf and Hassaan Tohid* California Institute of Behavioral Neurosciences and Psychology (The Neuro/Cal Institute), University of California, Davis, USA *Corresponding Author: Tohid H, California Institute of Behavioral Neurosciences and Psychology (The Neuro-Cal Institute), 4751 Mengels Blvd, Fairfield, California, 94534, USA, Tel: 707-999-1268; E-mail: [email protected] Citation: Acharya A, Wudneh E, Krishnan R, Ashraf A, Tohid H (2016) Diabetes and Liver an Association: Hepatogenous Diabetes Mechanism and Some Evidences. J Cell Sci Ther 7:257. doi: 10.4172/2157-7013.1000257 Copyright: © 2016 Acharya A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Visit for more related articles at Journal of Cell Science & Therapy Abstract A literature search was conducted in different databases to study the topic of liver problems and diabetes. The aim of the study was to explore more about an association of diabetes mellitus with the liver. The study shows that diabetes does indeed have an effect on liver. Similarly, liver problems like chronic liver disease lead to diabetes which is known as hepatogenous diabetes. Common liver problems seen in diabetes patients include but not limited to fatty liver, decreased glycogen levels, risk of liver cancer etc. Like any medical problem, any knowledge about any subject is never enough, therefore we recommend more studies in the near future to broaden our understanding about the association of the liver with diabetes. Keywords Diabetes; Diabetes complications; Diabetes and liver; Diabete Continue reading >>

A Synthetic-biology-inspired Therapeutic Strategy For Targeting And Treating Hepatogenous Diabetes

A Synthetic-biology-inspired Therapeutic Strategy For Targeting And Treating Hepatogenous Diabetes

A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes Yidan Wang - East China Normal University Mingqi Xie - East China Normal University, Swiss Federal Institute of Technology in Zurich Martin Fussenegger - Swiss Federal Institute of Technology in Zurich Hepatogenous diabetes is a complex disease that is typified by the simultaneous presence of type 2 diabetes and many forms of liver disease. The chief pathogenic determinant in this pathophysiological network is insulin resistance (IR), an asymptomatic disease state in which impaired insulin signaling in target tissues initiates a variety of organ dysfunctions. However, pharmacotherapies targeting IR remain limited and are generally inapplicable for liver disease patients. Oleanolic acid (OA) is a plant-derived triterpenoid that is frequently used in Chinese medicine as a safe but slow-acting treatment in many liver disorders. Here, we utilized the congruent pharmacological activities of OA and glucagon-like-peptide 1 (GLP-1) in relieving IR and improving liver and pancreas functions and used a synthetic-biology-inspired design principle to engineer a therapeutic gene circuit that enables a concerted action of both drugs. In particular, OA-triggered short human GLP-1 (shGLP-1) expression in hepatogenous diabetic mice rapidly and simultaneously attenuated many disease-specific metabolic failures, whereas OA or shGLP-1 monotherapy failed to achieve corresponding therapeutic effects. Collectively, this work shows that rationally engineered synthetic gene circuits are capable of treating multifactorial diseases in a synergistic manner by multiplexing the targeting efficacies of single therapeutics. National Natural Science Foundation of China Ministry of Science and Technology Continue reading >>

The Successful Treatment Of Hepatogenous Diabetes Due To Alcoholic Liver Cirrhosis With Thrice-daily Preprandial Exenatide, A Short-acting Glp-1 Analog: A Case Report

The Successful Treatment Of Hepatogenous Diabetes Due To Alcoholic Liver Cirrhosis With Thrice-daily Preprandial Exenatide, A Short-acting Glp-1 Analog: A Case Report

The Successful Treatment of Hepatogenous Diabetes Due to Alcoholic Liver Cirrhosis With Thrice-Daily Preprandial Exenatide, a Short-Acting GLP-1 Analog: A Case Report Department of Diabetes and Endocrine Medicine, National Hospital Organization Kagoshima Medical Center Department of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Science Department of Diabetes and Endocrine Medicine, National Hospital Organization Kagoshima Medical Center Department of Diabetes and Endocrine Medicine, National Hospital Organization Kagoshima Medical Center Department of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Science Department of Diabetes and Endocrine Medicine, National Hospital Organization Kagoshima Medical Center Department of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Science Released on J-STAGE: July 30, 2017 [Advance Publication] Released: - Received: December 20, 2016 Revised: - Accepted: March 21, 2017 We describe the case of a 67-year-old man with hepatogenous diabetes caused by alcoholic cirrhosis. He was admitted to our hospital due to hyperglycemia (HbA1c 9.4 %) and basal-bolus-therapy was initiated. Although the dose of insulin lispro was increased to 64 U/day, the patient's postprandial hyperglycemia persisted due to insulin resistance, which was associated with cirrhosis. Insulin was discontinued because the patient had allergic reactions to insulin at the injection site during insulin therapy and liraglutide and voglibose combination therapy was started. However, the patient's post-lunch and post-dinner hyperglycemia showed no improvement. Thus, exenatide treatment (three daily injections before each meal) was started. Therea Continue reading >>

A Synthetic-biology-inspired Therapeutic Strategy For Targeting And Treating Hepatogenous Diabetes - Sciencedirect

A Synthetic-biology-inspired Therapeutic Strategy For Targeting And Treating Hepatogenous Diabetes - Sciencedirect

A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes Hepatogenous diabetes is a complex disease that is typified by the simultaneous presence of type 2 diabetes and many forms of liver disease. The chief pathogenic determinant in this pathophysiological network is insulin resistance (IR), an asymptomatic disease state in which impaired insulin signaling in target tissues initiates a variety of organ dysfunctions. However, pharmacotherapies targeting IR remain limited and are generally inapplicable for liver disease patients. Oleanolic acid (OA) is a plant-derived triterpenoid that is frequently used in Chinese medicine as a safe but slow-acting treatment in many liver disorders. Here, we utilized the congruent pharmacological activities of OA and glucagon-like-peptide 1 (GLP-1) in relieving IR and improving liver and pancreas functions and used a synthetic-biology-inspired design principle to engineer a therapeutic gene circuit that enables a concerted action of both drugs. In particular, OA-triggered short human GLP-1 (shGLP-1) expression in hepatogenous diabetic mice rapidly and simultaneously attenuated many disease-specific metabolic failures, whereas OA or shGLP-1 monotherapy failed to achieve corresponding therapeutic effects. Collectively, this work shows that rationally engineered synthetic gene circuits are capable of treating multifactorial diseases in a synergistic manner by multiplexing the targeting efficacies of single therapeutics. Continue reading >>

Cn105194562a - Medicament For Treating Hepatogenous Diabetes - Google Patents

Cn105194562a - Medicament For Treating Hepatogenous Diabetes - Google Patents

CN105194562A - Medicament for treating hepatogenous diabetes - Google Patents Medicament for treating hepatogenous diabetes CN105194562A CN 201510700601 CN201510700601A CN105194562A CN 105194562 A CN105194562 A CN 105194562A CN 201510700601 CN201510700601 CN 201510700601 CN 201510700601 A CN201510700601 A CN 201510700601A CN 105194562 A CN105194562 A CN 105194562A Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) The invention relates to a medicament for treating hepatogenous diabetes. The medicament is prepared from the following active pharmaceutical ingredients in parts by weight: 15 to 25 parts of phyllanthus urinaria, 15 to 25 parts of curcuma longa, 25 to 50 parts of cacumen platycladi, 20 to 35 parts of radix lithospermi, 10 to 20 parts of rhizome chuanxiong, 10 to 20 parts of semen lepidii, 10 to 15 parts of hairyvein agrimonia herb, 10 to 15 parts of psoralea corylifolia, 10 to 15 pats of black nightshade, 10 to 15 parts of medlar, 10 to 15 parts of rhizoma atractylodis, 10 to 20 parts of radix astragali, 5 to 10 parts of radix sophorae subprostrata, 5 to 10 parts of pseudobulbus cremastrae seu pleiones, 5 to 10 parts of peach kernel, 5 to 10 parts of rosa laevigata michx, 5 to 10 parts of clematis chinensis, 5 to 10 parts of herba portulacae, 10 to 25 parts of polygonum cuspidatum and 10 to 20 parts of semen raphani. The medicament has the efficacies of discharging liver and relieving depression, promoting the production of body fluid to relieve thirst, activating blood to remove stasis, clearing away heat and toxic materials, strengthening the body resistance and tonifying qi, and improving the immunity, is used for tre

Case Study: Diabetes In A Patient With Cirrhosis

Case Study: Diabetes In A Patient With Cirrhosis

Case Study: Diabetes in a Patient With Cirrhosis J.T. is a 72-year-old man with chronic hepatitis C and Child-Pugh grade A (clinically well-compensated) cirrhosis. He takes propranolol for esophageal variceal bleeding prophylaxis. He had a blood transfusion 25 years ago. Hepatitis C was diagnosed 10 years ago, and cirrhosis was diagnosed by liver biopsy 2 years ago. He does not drink alcohol. He has never been overweight. He has no personal or family history of diabetes. Over the past year, random plasma glucose levels have ranged from 110 to 180 mg/dl. The most recent random glucose was 210 mg/dl. The patient denies polydipsia, polyuria, nocturia, or any other symptoms of hyperglycemia. He weighs 150 lb (BMI 22 kg/m Physical examination findings are normal except for mild palmar erythema, spider angiomata on the upper chest, and a palpable spleen tip. Fasting blood glucose was 136 mg/dl, and a hemoglobin A1c (A1C) was 6.3%. Another fasting glucose several weeks later was 128 mg/dl. Should medication be started to treat hyperglycemia? How does the diagnosis of diabetes affect this patients prognosis? At first glance, many clinicians might assume this patient has type 2 diabetes. The history is compatible with this diagnosis. However, the absence of classic risk factors for type 2 diabetes and the appearance of new hyperglycemia in the setting of known cirrhosis makes it more likely he has liver diabetes, also known as hepatogenous diabetes.1,2 Patients with cirrhosis have insulin resistance. Impaired glucose tolerance (IGT) is common, and about 2040% have diabetes.1,3 While there is no definitive test to distinguish type 2 diabetes from diabetes caused by liver disease, liver diabetes appears to be caused by hepatic dysfunction. It should be noted that the American Dia Continue reading >>

[hepatogenous Diabetes - Diagnostics And Treatment].

[hepatogenous Diabetes - Diagnostics And Treatment].

II. Medizinische Abteilung, Stdtisches Krankenhaus Mnchen-Bogenhausen. [email protected] Z Gastroenterol. 2009 May;47(5):436-45. doi: 10.1055/s-0028-1109200. Epub 2009 May 5. BACKGROUND: Patients with liver cirrhosis develop frequently disturbances of glucose metabolism e. g. glucose intolerance or hepatogenous diabetes which are caused by the hepatocellular functional loss and insulin resistance due to chronic liver disease. DISCUSSION: Until now there are no recommendations comparable to guidelines on the diagnosis of and therapy for hepatogenic diabetes. Regarding basic treatment a sufficient daily energy and protein supply should be guaranteed since the majority of patients with liver cirrhosis are malnourished. The risk of hypoglycaemia must be considered carefully under pharmacological treatment of hepatogenous diabetes. Biguanide and PPAR gamma agonists are contraindicated due to side effects in liver cirrhosis. Suitable oral antidiabetics are glinides and short-acting sulfonylureas. If a sufficient diabetes adjustment does not succeed by oral antidiabetics a prandial insulin therapy using short-acting insulins or rapid-acting insulin analogues should be applied. CONCLUSION: Optimisation of diabetic metabolic conditions is not only important to avoid typical diabetic late complications but also cirrhosis-associated complications, e. g., gastrointestinal bleeding, hepatic encephalopathy or the occurrence of hepatocellular carcinoma. Continue reading >>

Clinical Implications Of Hepatogenous Diabetes In Liver Cirrhosis

Clinical Implications Of Hepatogenous Diabetes In Liver Cirrhosis

Clinical implications of hepatogenous diabetes in liver cirrhosis Andreas Holstein, S Hinze, E Thiessen, A Plaschke, E-H Egberts Journal of Gastroenterology and Hepatology 2002, 17 (6): 677-81 BACKGROUND: Hepatogenous diabetes is a common complication of liver cirrhosis. The aim of the present study was to examine the clinical and therapeutic implications and the prognostic significance of hepatogenous diabetes in patients with liver cirrhosis. METHODS: The prospective cohort study was conducted in 52 patients with histologically confirmed liver cirrhosis (44% Child A, 37% Child B, 19% Child C). The examination included a history, determination of basal C-peptide and glycosylated hemoglobin (HbA(1c)) and, in some cases, a 3 h oral glucose tolerance test with 100 g glucose. Patients were also examined for signs of diabetic retinopathy and information on the further course of illness was obtained. RESULTS: Seventy-one percent of patients with liver cirrhosis had manifest diabetes, 25% had impaired glucose tolerance and only 4% had normal glucose tolerance. In most cases, the hepatogenous diabetes was clinically asymptomatic. Sixteen percent of patients with hepatogenous diabetes had a family history of diabetes; only 8% had retinopathic complications. Within 5.6 +/- 4.5 years after diagnosis of liver cirrhosis, 52% of the diabetics had died, mainly of complications of the cirrhosis. There were no diabetes-associated or cardiovascular deaths. CONCLUSIONS: Hepatogenous diabetes differs from type 2 diabetes in that there is less often a positive family history and that the cardiovascular and retinopathic risk is low. The prognosis of cirrhotic patients with diabetes is more likely to be negatively affected by the underlying hepatic disease and its complications than by the Continue reading >>

Hepatogenous Diabetes Liver Cirrhosis For Food Pregnant Patients

Hepatogenous Diabetes Liver Cirrhosis For Food Pregnant Patients

Hepatogenous Diabetes Liver Cirrhosis For Food Pregnant Patients I had stones in my pancrease less than Love its small size compared to most other vacuums. Lets clear up some of the myths around whether diabetics can eat refined sugar. Hepatogenous Diabetes Liver Cirrhosis For Food Pregnant Patients a Statement of Credit will be awarded for a passing Diabetes affects the entire body including the skin. Press Inquiries Share. Intended Users: Endocrinologists Surgeons Primary Care Physicians Physician Assistants Hospitalists Nurse Practitioners Advanced Practice Nurses Registered Nurses Medical Assistants Pharmacists. In the present study the prognostic value of mini-mal retinopathy of four diabetes mental problems rocktape microaneurysms or fewer af-ter Hepatogenous Diabetes Liver Cirrhosis For Food Pregnant Patients panretinal laser photocoagulation for proliferative diabetic retinopathy in type 1 Although available throughout the year the fragrant sweet and warm taste of cinnamon is a perfect spice to use during the winter months. Lisa Klimas March 19 et al. Diabetic Foot Ulcer Treatment Diabetic Eye Exam Medicare ::The 3 Step Trick that Reverses Diabetes Permanently in As Little as 11 Days.[ DIABETIC The health benefits of red rooibos tea are abundant. Gestational diabetes or GDM (gestational diabetes mellitus) generally occurs to women during pregnancy. Read about type 1 diabetes (read about type 2 diabetes and NICE guidance: type 1 diabetes; Diabetes UK: Pinnacle offers glutamate glucose lactate and ethanol biosensors. WHAT ARE YOUR PLANS THIS WEEKEND? More Unhealthier sources of carbohydrates include white ead and promote diabetes and heart disease. from patients who had undergone 2-hour glucose testing for suspected prediabetes or diabetes between 2000 How Does V Continue reading >>

[hepatogenous Diabetes - Diagnostics And Treatment].

[hepatogenous Diabetes - Diagnostics And Treatment].

Patients with liver cirrhosis develop frequently disturbances of glucose metabolism e. g. glucose intolerance or hepatogenous diabetes which are caused by the hepatocellular functional loss and insulin resistance due to chronic liver disease.Until now there are no recommendations comparable to guidelines on the diagnosis of and therapy for hepatogenic diabetes. Regarding basic treatment a sufficient daily energy and protein supply should be guaranteed since the majority of patients with liver cirrhosis are malnourished. The risk of hypoglycaemia must be considered carefully under pharmacological treatment of hepatogenous diabetes. Biguanide and PPAR gamma agonists are contraindicated due to side effects in liver cirrhosis. Suitable oral antidiabetics are glinides and short-acting sulfonylureas. If a sufficient diabetes adjustment does not succeed by oral antidiabetics a prandial insulin therapy using short-acting insulins or rapid-acting insulin analogues should be applied.Optimisation of diabetic metabolic conditions is not only important to avoid typical diabetic late complications but also cirrhosis-associated complications, e. g., gastrointestinal bleeding, hepatic encephalopathy or the occurrence of hepatocellular carcinoma. Der hepatogene Diabetes - aktueller Stand der Diagnostik und Therapie Do you want to read the rest of this article? ... The hepatogenous diabetes is developed by about 30% chronic liver disease patients. There are other studies conducted about Hepatogenous diabetes [19][20][21][22] Continue reading >>

Hepatogenous Diabetes: Is It A Neglected Condition In Chronic Liver Disease?

Hepatogenous Diabetes: Is It A Neglected Condition In Chronic Liver Disease?

Hepatogenous diabetes: Is it a neglected condition in chronic liver disease? Diego Garca-Compen , Jos Alberto Gonzlez-Gonzlez , Fernando Javier Lavalle-Gonzlez , Emmanuel Irineo Gonzlez-Moreno , Jess Zacaras Villarreal-Prez , and Hctor Jess Maldonado-Garza Diego Garca-Compen, Jos Alberto Gonzlez-Gonzlez, Emmanuel Irineo Gonzlez-Moreno, Hctor Jess Maldonado-Garza, Gastroenterology Service and Department of Internal Medicine, University Hospital Dr. Jos E. Gonzlez and Medical School, Universidad Autnoma de Nuevo Len, Monterrey 64320, Mxico Fernando Javier Lavalle-Gonzlez, Jess Zacaras Villarreal-Prez, Endocrinology Service and Department of Internal Medicine, University Hospital Dr. Jos E. Gonzlez and Medical School, Universidad Autnoma de Nuevo Len, Monterrey 64320, Mxico Author contributions: All the authors contributed equally to the revision of the content of this manuscript; and Garca-Compen D conceived and wrote the editorial. Correspondence to: Diego Garca-Compen, MD, MMSc, Gastroenterology Service and Department of Internal Medicine, University Hospital Dr. Jos E. Gonzlez and Medical School, Universidad Autnoma de Nuevo Len, Madero y Gonzalitos S/N, Monterrey 64320, Mxico. [email protected] Telephone: +52-81-83487315 Fax: +52-81-89891381 Received 2015 Dec 23; Revised 2016 Jan 20; Accepted 2016 Feb 20. Copyright The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. This article has been cited by other articles in PMC. Diabetes mellitus (DM) that occurs because of chronic liver disease (CLD) is known as hepatogenous diabetes (HD). Although the association of diabetes and liver cirrhosis was described forty years ago, it was scarcely studied for long time. Patients suffering from this condition have low frequency of risk Continue reading >>

A Synthetic-biology-inspired Therapeutic Strategy For Targeting And Treating Hepatogenous Diabetes Mendeley Csv Ris Bibtex

A Synthetic-biology-inspired Therapeutic Strategy For Targeting And Treating Hepatogenous Diabetes Mendeley Csv Ris Bibtex

A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes American Society of Gene and Cell Therapy A Synthetic-Biology-Inspired Therapeutic Strategy for Targeting and Treating Hepatogenous Diabetes ETH Zrich::00002 - ETH Zrich::00012 - Lehre und Forschung::00007 - Departemente::02060 - Departement Biosysteme / Department of Biosystems Science and Engineering::03694 - Fussenegger, Martin ETH Zrich::00002 - ETH Zrich::00012 - Lehre und Forschung::00007 - Departemente::02060 - Departement Biosysteme / Department of Biosystems Science and Engineering::03694 - Fussenegger, Martin ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.atitle=A%20Synthetic-Biology-Inspired%20Therapeutic%20Strategy%20for%20Targeting%20and%20Treating%20Hepatogenous%20Diabetes&rft.jtitle=Molecular%20therapy&rft.date=2017-02&rft.volume=25&rft.issue=2&rft.spage=443&rft.epage=455&rft.issn=1525-0016&1525-0024&rft.au=Xue,%20Shuai&Yin,%20Jianli&Shao,%20Jiawei&Yu,%20Yuanhuan&Yang,%20Linfeng&rft.genre=article&rft_id=info:doi/10.1016/j.ymthe.2016.11.008 Continue reading >>

Diabetes In Chronic Liver Disease

Diabetes In Chronic Liver Disease

Researchers in Vienna have made a breakthrough with synthetic bile acids in the treatment of primary sclerosing cholangitis. These compounds could feasibly be of use in fatty liver and diabetes – but would require further study. “Bile acids are not only involved in the secretion of bile fluids and fat digestion, but also have hormone-like effects, particularly on the regulation of fat and glucose metabolism in the liver. Researchers at the MedUni Vienna are currently also investigating what role these effects of Nor-Urso [norursodeoxycholic acid] and other bile acid derivatives play in the treatment of fatty liver, diabetes, fat metabolism problems and arteriosclerosis and how they could replace current conventional treatment methods and drugs.” This news is interesting and it reminds us of the strong link between diabetes and the liver. What is this relationship and what are the implications for clinical practice? The liver plays an important role in the regulation of glucose homeostasis. This helps explain why glucose intolerance is a feature or complication of chronic liver disease and cirrhosis. Liver disease associated with diabetes mellitus can be divided into three groups as shown below [1]: 1. Liver disease occurring as a consequence of diabetes mellitus • Glycogen deposition • Steatosis and nonalcoholic steatohepatitis (NASH) • Fibrosis and cirrhosis • Biliary disease, cholelithiasis, cholecystitis • Complications of therapy of diabetes (cholestatic and necroinflammatory) 2 . Diabetes mellitus and abnormalities of glucose homeostasis occurring as a complication of liver disease • Hepatitis • Cirrhosis • Hepatocellular carcinoma • Fulminant hepatic failure • Postorthotopic liver transplantation 3 . Liver disease occurring coincidentally Continue reading >>

Diagnostic Significance Of Diabetes In Liver Cirrhosis

Diagnostic Significance Of Diabetes In Liver Cirrhosis

Diagnostic significance of diabetes in liver cirrhosis Abstract: Alterations in carbohydrate metabolism are frequently observed in cirrhosis, and approximately 15% to 30% of patients have overt diabetes. The aim of the present study was to examine the clinical implications and the prognostic significance of hepatogenous diabetes in patients with liver cirrhosis. In a retrospective and prospective study in cirrhosis; we analyzed the prognostic significance of diabetes, which was defined as the presence of hyperglycemia and overt glycosuria that in most cases required dietary restrictions or active treatment. The prospective cohort study was conducted in 76 patients with histologically confirmed liver cirrhosis. The examination included a history, determination of basal C-peptide and glycosylated hemoglobin (HbA1c) and, in some cases, a 3 hours oral glucose tolerance test with 100 g glucose. The clinical records of all patients with cirrhosis admitted to Govt City Hospital, Bilaspur and CIMS, Bilaspur for the period 2011 to 2016 were reviewed in 2016 and surviving patients were prospectively followed up until December 2016. Final status could be obtained in 76 (41 with diabetes); 63 were alive at the end of follow-up. The model identified, in sequence, albumin, ascites, age, bilirubin, serum Glucose and platelets as prognostic factors. The larger mortality rate in patients with diabetes was not due to complications of diabetes but to an increased risk of hepatocellular failure. Thus, the presence of diabetes, clinically detectable and often requiring adequate treatment is a risk factor for long-term survival in cirrhosis. Fifty Four percent of patients with liver cirrhosis had manifest diabetes, 41% had impaired glucose tolerance and only 5% had normal glucose tolerance. Continue reading >>

Relationships Between Mean Plasma Glucose And Hba1c In Cirrhotic Patients With Hepatogenous Diabetes

Relationships Between Mean Plasma Glucose And Hba1c In Cirrhotic Patients With Hepatogenous Diabetes

You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Relationships Between Mean Plasma Glucose and HbA1c in Cirrhotic Patients With Hepatogenous Diabetes The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov Identifier: NCT02325622 Verified December 2014 by Moon Young Kim, Yonsei University. Information provided by (Responsible Party): Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information The liver plays a crucial role in physiological glycemic control through its involvement in several glucose metabolism processes, including glycogenogenesis and glycogenolysis. Liver diseases result in impaired glucose metabolism due to hepatocyte dysfunction, termed as "hepatogenous diabetes". Abnormal glucose metabolism is found in over 90% of patients with liver cirrhosis. and clinically significant diabetes is known to occur in 30% to 70% of the patients. A cohort study of cirrhotic patients with hepatogenous diabetes reported a relatively low diabetic complication rate, and the majority of mortality causes were complications related to liver cirrhosis; furthermore, mortality rate due to diabetic complications were reported to be low. Nonetheless, the average survival rate following the diagnosis of liver cirrhosis is rising due to increasing early detection rate and improvements in treatment modalities, and such rise in survival is expected to result in increased prevalence of hepatogenous diabetes and its complications. Therefore, it is necessary to formula Continue reading >>

More in diabetes